FDA Approves Icotrokinra for Plaque Psoriasis: First Oral IL-23 Antagonist

Executive Brief

News Report

The News: FDA approves icotrokinra, the first oral IL-23 receptor antagonist for plaque psoriasis.
Clinical Win: This approval offers a new oral treatment option for patients with moderate-to-severe plaque psoriasis.
Target Specialty: Dermatology

Key Data at a Glance

PASI 75 Response Rate: 65% icotrokinra vs 20% placebo
Trial Enrollment: 1,500 patients
Primary Endpoint: PASI 75 at week 16

The FDA has approved icotrokinra (Icotyde), the first oral interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older. This approval, announced in March 2026, represents a significant advancement in psoriasis management, providing an alternative to traditional biologic injections.

Clinical Context

Plaque psoriasis is a chronic autoimmune condition characterized by the rapid proliferation of skin cells, leading to thick, red, scaly patches. It affects approximately 7.5 million adults in the United States, and many patients experience significant physical and psychological burdens due to the disease. Current treatment options include topical therapies, phototherapy, and systemic agents, including biologics that target specific immune pathways. However, many patients prefer oral medications due to the convenience and ease of administration compared to injections. Icotrokinra, as an oral peptide, offers a novel mechanism of action by selectively inhibiting the IL-23 receptor, which plays a crucial role in the inflammatory process of psoriasis. This new treatment option may help fill the existing gap in care for patients who are candidates for systemic therapy but prefer not to use injectable biologics.

Key Findings

The clinical trials showed icotrokinra reduced the severity of plaque psoriasis by significant margins compared to placebo, demonstrating its efficacy in managing the condition.
Event rates: 65% of patients treated with icotrokinra achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) compared to 20% with placebo [1].
The primary endpoint was the proportion of patients achieving PASI 75 at week 16 [1].

Safety & Tolerability

The trial enrolled 1,500 patients with moderate-to-severe plaque psoriasis, providing robust data on the drug's effectiveness and safety profile [1].

What This Means for Clinical Practice

Icotrokinra is used in patients meeting the trial-defined criteria, including adults and adolescents with moderate-to-severe plaque psoriasis. The significant efficacy shown in clinical trials supports its use as a viable option for patients who prefer oral therapies over injections. Clinicians should consider this new treatment in their management plans, especially for patients who have struggled with adherence to injectable biologics or have expressed a preference for oral medications. As more data emerges on long-term outcomes and safety, the integration of icotrokinra into treatment guidelines will become clearer, prompting further discussions on optimizing psoriasis care.

The approval of icotrokinra marks a pivotal moment in psoriasis treatment, potentially reshaping how clinicians approach therapy selection for their patients. As the landscape of psoriasis management evolves, it will be essential for healthcare providers to stay informed about new therapies and their implications for patient care.

Clinical Perspective

Workflow: The introduction of icotrokinra may streamline treatment options for patients who prefer oral medications.

Economics: Oral therapies may reduce costs associated with injection supplies and administration.

Patient Outcomes: Improved adherence and patient satisfaction are expected outcomes with the availability of an oral option.

Dr. Rohan Gupta, Dermatology

References

NEJM — Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

FDA Approves Icotrokinra for Plaque Psoriasis: First Oral IL-23 Antagonist

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

IL-17 vs IL-23 vs TNF Inhibitors: 2025 Comparison for Plaque Psoriasis Treatment

FDA Approves Icotrokinra for Moderate to Severe Plaque Psoriasis: Oral IL-23 Antagonist for Patients 12 and Older

FDA Approves Icotyde for Moderate to Severe Plaque Psoriasis: New Oral IL-23 Antagonist

Verified HCP Portal